Eye Infections, Bacterial Clinical Trial
Official title:
Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers
To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one
instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day
2).
To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day
treatment period
The aim of the present study was to compare ocular tolerance and safety after repeated instillations of T1225 1% and 1.5% eye drops and vehicle and to assess the residual azithromycin concentrations in tear, ocular conjunctiva and plasma samples, approximately 12 hours after the last Investigational Medicinal Product instillation. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00324168 -
Steroids for Corneal Ulcers Trial
|
Phase 4 | |
| Completed |
NCT00356850 -
Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00357292 -
Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00356772 -
Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00357539 -
Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04981860 -
Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine
|
Phase 4 |